These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17699257)

  • 1. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
    Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
    Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
    Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
    Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
    Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
    Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
    Ona ET; Danguilan RA; Africa J; Cabanayan-Casasola CB; Antonio ZL; Gutierrez-Marbella MA; dela Cruz R; Bumanglag N; Espedilla ME
    Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Skaletsky M; Norfolk ER; Brown RE; Hartle JE; Potdar S
    Ann Clin Lab Sci; 2004; 34(2):209-13. PubMed ID: 15228236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
    Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
    Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
    Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
    Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab induction in kidney transplantation.
    Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S
    Clin Transpl; 2005; ():343-54. PubMed ID: 17424750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy.
    Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Norfolk ER; Blasick TM; Lun M; Brown RE; Hartle JE; Potdar S
    Am J Transplant; 2005 Mar; 5(3):604-7. PubMed ID: 15707416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation.
    Ashokkumar C; Shapiro R; Tan H; Ningappa M; Elinoff B; Fedorek S; Sun Q; Higgs BW; Randhawa P; Humar A; Sindhi R
    Transplantation; 2011 Aug; 92(4):433-8. PubMed ID: 21747326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotyping of interstitial infiltrate does not distinguish between BK virus nephropathy and acute cellular rejection.
    Rogers NM; Russ GR; Cooper J; Coates PT
    Nephrology (Carlton); 2009 Feb; 14(1):118-22. PubMed ID: 19143944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute cellular rejection with CD20-positive lymphoid clusters in kidney transplant patients following lymphocyte depletion.
    Kayler LK; Lakkis FG; Morgan C; Basu A; Blisard D; Tan HP; McCauley J; Wu C; Shapiro R; Randhawa PS
    Am J Transplant; 2007 Apr; 7(4):949-54. PubMed ID: 17331114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
    Magliocca JF; Knechtle SJ
    Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.